EQS-News

MeVis publishes figures for financial year 2022/2023 and forecast for 2023/2024 - Seite 2

For the 2023/2024 financial year, sales are now expected to increase slightly year-on-year to between € 18.0 million and € 18.5 million. In addition to the slight increase in sales with the customer Hologic, sales in the lung and liver area are also expected to increase slightly. We expect a slight decline in the area of development services. For earnings before interest and taxes (EBIT), we expect stability in the range of € 4.5 million to € 5.0 million. The forecast slight growth in sales and the simultaneous increase in personnel costs and other operating expenses are key drivers for the EBIT outlook.

The half-year financial report for the 2023/2024 financial year will be published on May 27, 2024.

 

Contact:
Kirchhoff, Marcus / CEO

---

29.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---

Language:	English
Company:	MeVis Medical Solutions AG
	Caroline-Herschel-Str. 1
	28359 Bremen
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	http://www.mevis.de
ISIN:	DE000A0LBFE4
WKN:	A0LBFE
Listed:	Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1825455

End of News	EQS News Service

1825455  29.01.2024 CET/CEST